Dr. Chaoyang Li
Claim this profileDelaware Health Center-Grady Cancer Center
Studies Skin Cancer
Studies Melanoma
2 reported clinical trials
8 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRAF positive
2Melanoma
Stage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Chaoyang Li is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Chaoyang Li
Clinical Trial Related8 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Chaoyang Li has experience with
- Ipilimumab
- Nivolumab
- Sargramostim
- Carboplatin
- Gemcitabine Hydrochloride
- Paclitaxel
Breakdown of trials Chaoyang Li has run
Cutaneous Melanoma
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chaoyang Li specialize in?
Chaoyang Li focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Chaoyang Li currently recruiting for clinical trials?
Yes, Chaoyang Li is currently recruiting for 2 clinical trials in Delaware Ohio. If you're interested in participating, you should apply.
Are there any treatments that Chaoyang Li has studied deeply?
Yes, Chaoyang Li has studied treatments such as Ipilimumab, Nivolumab, Sargramostim.
What is the best way to schedule an appointment with Chaoyang Li?
Apply for one of the trials that Chaoyang Li is conducting.
What is the office address of Chaoyang Li?
The office of Chaoyang Li is located at: Delaware Health Center-Grady Cancer Center, Delaware, Ohio 43015 United States. This is the address for their practice at the Delaware Health Center-Grady Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.